Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
Contact Dermatitis · 2023
DOI: 10.1111/cod.14276 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Contact Dermatitis, 2023. Verfasst von Esmé Kamphuis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dermatitis, Allergic Contact, Eczema. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, Sanofi.
Abstract (Originalsprache)
Background
Real‐world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.
Objectives
To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.
Methods
This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib‐treated patients. Adverse events were monitored during each visit.
Results
Thirty‐eight patients were included, of which 32 patients had HE. At Week 16, EASI‐75 was achieved by 50.0%. Absolute cutoff score NRS‐pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Dermatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
ORCID-Profile: Esmé Kamphuis, Laura Loman, Henry L Han, Geertruida L E Romeijn, Klaziena Politiek, Marie L A Schuttelaar
Förderung
- Pfizer
- Sanofi
Zitieren
APA
Kamphuis, E., Loman, L., Han, H. L., Romeijn, G. L. E., Politiek, K., & Schuttelaar, M. L. A. (2023). Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. https://doi.org/10.1111/cod.14276
Vancouver
Kamphuis E, Loman L, Han HL, Romeijn GLE, Politiek K, Schuttelaar MLA. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. 2023. doi:10.1111/cod.14276
BibTeX
@article{Kamphuis2023,
author = {Kamphuis, Esmé and Loman, Laura and Han, Henry L and Romeijn, Geertruida L E and Politiek, Klaziena and Schuttelaar, Marie L A},
title = {Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry},
journal = {Contact Dermatitis},
year = {2023},
doi = {10.1111/cod.14276}
}
EUVIMED